Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment
NCT02622763 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3
Last updated 2020-02-28
Summary
Intralesional Tolerogenic Dendritic Cells in Crohn's Disease Treatment.
Conditions
Interventions
- BIOLOGICAL
-
Tolerogenic Dendritic Cells
Intralesional administration
Sponsors & Collaborators
-
Fundacion Clinic per a la Recerca Biomédica
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-11-30
- Primary Completion
- 2019-05-05
- Completion
- 2019-05-05
Countries
- Spain
Study Locations
More Related Trials
-
Safety and Efficacy of MT-1303 in Subjects With Moderate to Severe Active Crohn's Disease
NCT02378688 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Moderate to Severe Refractory Crohn's Disease
NCT06721962 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Open Label Extension Study to Protocol C2/13/DR-6MP-02
NCT01433432 ·Status: WITHDRAWN ·Phase: PHASE2
-
Efficacy and Safety Trial of RPC1063 for Moderate to Severe Crohn's Disease
NCT02531113 ·Status: COMPLETED ·Phase: PHASE2
-
Glycan Supplementation on a Human Model of Crohn's Disease Initiation and Progression
NCT06727253 ·Status: RECRUITING ·Phase: NA
-
Autologous Hematopoietic Stem Cell Transplantation for Crohn's Disease Treatment
NCT01932658 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Phase II Study of HMPL-004 in Subjects With Crohn's Disease
NCT00655733 ·Status: COMPLETED ·Phase: PHASE2
-
Extension Study of MT-1303 in Subjects With Crohn's Disease
NCT02389790 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease
NCT01203631 ·Status: COMPLETED ·Phase: PHASE2
-
Immune Ablation and Stem Cell Support for Crohn's Disease
NCT00179842 ·Status: WITHDRAWN ·Phase: PHASE2
-
Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease
NCT06673134 ·Status: ACTIVE_NOT_RECRUITING
-
MSC Intratissular Injection in Crohn Disease Patients
NCT03901235 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
NCT06233461 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase II Study to Assess the Efficacy and Safety of Olokizumab in Patients With Crohn's Disease
NCT01635621 ·Status: WITHDRAWN ·Phase: PHASE2
-
Low Dose IL-2 for the Treatment of Crohn's Disease
NCT04263831 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease
NCT04102111 ·Status: TERMINATED ·Phase: PHASE2
-
Crohn's Disease Stem Cell Transplantation
NCT00271947 ·Status: TERMINATED ·Phase: PHASE2
-
A Study of TRK-170 for the Treatment of Crohn's Disease
NCT01345799 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Regulatory T-cells and Crohn's Disease
NCT02060318 ·Status: COMPLETED
-
A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]
NCT00160524 ·Status: COMPLETED ·Phase: PHASE3
-
A Six Week Efficacy, Safety and Tolerability Study of V565 in Crohn's Disease
NCT02976129 ·Status: COMPLETED ·Phase: PHASE2
-
An Investigational Study of Experimental Medication BMS-986165 in Participants With Moderate to Severe Crohn's Disease
NCT03599622 ·Status: TERMINATED ·Phase: PHASE2
-
Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
NCT02403323 ·Status: TERMINATED ·Phase: PHASE3
-
Induced Adult Refractory Active Crohn's Disease Clinical Relieving by Using Thalidomide
NCT02956538 ·Status: UNKNOWN ·Phase: EARLY_PHASE1